327 related articles for article (PubMed ID: 15629872)
1. Randomized double-blind comparison of serotonergic (Citalopram) versus noradrenergic (Reboxetine) reuptake inhibitors in outpatients with somatoform, DSM-IV-TR pain disorder.
Aragona M; Bancheri L; Perinelli D; Tarsitani L; Pizzimenti A; Conte A; Inghilleri M
Eur J Pain; 2005 Feb; 9(1):33-8. PubMed ID: 15629872
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the effectiveness of reboxetine versus fluoxetine in patients with atypical depression: a single-blind, randomized clinical trial.
Taner E; Demir EY; Cosar B
Adv Ther; 2006; 23(6):974-87. PubMed ID: 17276965
[TBL] [Abstract][Full Text] [Related]
3. Differential prediction of first clinical response to serotonergic and noradrenergic antidepressants using the loudness dependence of auditory evoked potentials in patients with major depressive disorder.
Juckel G; Pogarell O; Augustin H; Mulert C; Müller-Siecheneder F; Frodl T; Mavrogiorgou P; Hegerl U
J Clin Psychiatry; 2007 Aug; 68(8):1206-12. PubMed ID: 17854244
[TBL] [Abstract][Full Text] [Related]
4. Severity of depression and response to antidepressants: GENPOD randomised controlled trial.
Wiles NJ; Mulligan J; Peters TJ; Cowen PJ; Mason V; Nutt D; Sharp D; Tallon D; Thomas L; O'Donovan MC; Lewis G
Br J Psychiatry; 2012 Feb; 200(2):130-6. PubMed ID: 22194183
[TBL] [Abstract][Full Text] [Related]
5. Differential effects of reboxetine and citalopram on hand-motor function in patients suffering from major depression.
Hegerl U; Mergl R; Henkel V; Pogarell O; Müller-Siecheneder F; Frodl T; Juckel G
Psychopharmacology (Berl); 2005 Feb; 178(1):58-66. PubMed ID: 15316714
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and tolerability of reboxetine compared with citalopram: a double-blind study in patients with major depressive disorder.
Langworth S; Bodlund O; Agren H
J Clin Psychopharmacol; 2006 Apr; 26(2):121-7. PubMed ID: 16633139
[TBL] [Abstract][Full Text] [Related]
7. Prediction of the response to citalopram and reboxetine in post-stroke depressed patients.
Rampello L; Chiechio S; Nicoletti G; Alvano A; Vecchio I; Raffaele R; Malaguarnera M
Psychopharmacology (Berl); 2004 Apr; 173(1-2):73-8. PubMed ID: 14685645
[TBL] [Abstract][Full Text] [Related]
8. Different gender response to serotonergic and noradrenergic antidepressants. A comparative study of the efficacy of citalopram and reboxetine.
Berlanga C; Flores-Ramos M
J Affect Disord; 2006 Oct; 95(1-3):119-23. PubMed ID: 16782204
[TBL] [Abstract][Full Text] [Related]
9. Reboxetine and citalopram in panic disorder: a single-blind, cross-over, flexible-dose pilot study.
Seedat S; van Rheede van Oudtshoorn E; Muller JE; Mohr N; Stein DJ
Int Clin Psychopharmacol; 2003 Sep; 18(5):279-84. PubMed ID: 12920388
[TBL] [Abstract][Full Text] [Related]
10. No effects of antidepressants on negative symptoms in schizophrenia.
Hinkelmann K; Yassouridis A; Kellner M; Jahn H; Wiedemann K; Raedler TJ
J Clin Psychopharmacol; 2013 Oct; 33(5):686-90. PubMed ID: 23857309
[TBL] [Abstract][Full Text] [Related]
11. Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor.
Lenox-Smith AJ; Jiang Q
Int Clin Psychopharmacol; 2008 May; 23(3):113-9. PubMed ID: 18408525
[TBL] [Abstract][Full Text] [Related]
12. Noradrenaline-selective versus serotonin-selective antidepressant therapy: differential effects on social functioning.
Dubini A; Bosc M; Polin V
J Psychopharmacol; 1997; 11(4 Suppl):S17-23. PubMed ID: 9438229
[TBL] [Abstract][Full Text] [Related]
13. Citalopram plus reboxetine in treatment-resistant obsessive-compulsive disorder.
Fontenelle LF; Mendlowicz MV; Miguel EC; Versiani M
World J Biol Psychiatry; 2005; 6(1):57-9. PubMed ID: 16097406
[TBL] [Abstract][Full Text] [Related]
14. Increased positive versus negative affective perception and memory in healthy volunteers following selective serotonin and norepinephrine reuptake inhibition.
Harmer CJ; Shelley NC; Cowen PJ; Goodwin GM
Am J Psychiatry; 2004 Jul; 161(7):1256-63. PubMed ID: 15229059
[TBL] [Abstract][Full Text] [Related]
15. Sex differences in depressive symptoms and tolerability after treatment with selective serotonin reuptake inhibitor antidepressants: Secondary analyses of the GENPOD trial.
Gougoulaki M; Lewis G; Nutt DJ; Peters TJ; Wiles NJ; Lewis G
J Psychopharmacol; 2021 Aug; 35(8):919-927. PubMed ID: 33637001
[TBL] [Abstract][Full Text] [Related]
16. Nicotine, but not mecamylamine, enhances antidepressant-like effects of citalopram and reboxetine in the mouse forced swim and tail suspension tests.
Andreasen JT; Redrobe JP
Behav Brain Res; 2009 Jan; 197(1):150-6. PubMed ID: 18786574
[TBL] [Abstract][Full Text] [Related]
17. Diminished neural processing of aversive and rewarding stimuli during selective serotonin reuptake inhibitor treatment.
McCabe C; Mishor Z; Cowen PJ; Harmer CJ
Biol Psychiatry; 2010 Mar; 67(5):439-45. PubMed ID: 20034615
[TBL] [Abstract][Full Text] [Related]
18. Adverse effects from antidepressant treatment: randomised controlled trial of 601 depressed individuals.
Crawford AA; Lewis S; Nutt D; Peters TJ; Cowen P; O'Donovan MC; Wiles N; Lewis G
Psychopharmacology (Berl); 2014 Aug; 231(15):2921-31. PubMed ID: 24525810
[TBL] [Abstract][Full Text] [Related]
19. Reboxetine, a selective norepinephrine reuptake inhibitor, is an effective and well-tolerated treatment for panic disorder.
Versiani M; Cassano G; Perugi G; Benedetti A; Mastalli L; Nardi A; Savino M
J Clin Psychiatry; 2002 Jan; 63(1):31-7. PubMed ID: 11838623
[TBL] [Abstract][Full Text] [Related]
20. [Comparison of reboxetine and sertraline in terms of efficacy and safety in major depressive disorder].
Eker SS; Akkaya C; Akgöz S; Sarandöl A; Kirli S
Turk Psikiyatri Derg; 2005; 16(3):153-63. PubMed ID: 16180148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
